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The growth of prenatal diagnosis and selective abortion has provided profound relief for many couples, but it has also aroused opposition on moral grounds and has been criticised as overshadowing other approaches to the reduction of perinatal deaths and handicapping disorders of childhood. Fundamental research into the causes and true prevention of birth defects, especially neural defect, could be neglected as a consequence of health service planners' use of abortion as the definitive answer to birth defect. ' Screening by measurement of the maternal serum alphafetoprotein is the first "genetic" tool that could be applied to the entire pregnant population, so the recent report from a working group on maternal serum alphafetoprotein screening2 prompts us to attempt to put into perspective, firstly, an assessment of the benefits and risks of maternal serum alphafetoprotein screening programmes in averting the birth of affected babies; secondly, the value that such programmes may coincidentally have in identifying high-risk but salvageable fetuses; and, thirdly, the possibility of true prevention of neural tube defect by supplementing the mother's diet.
Alphafetoprotein and the fetus-Alphafetoprotein is a normal fetal protein that passes into the amniotic fluid, rising to a peak at the end of the first trimester and then declining rapidly. The alphafetoprotein derived from the fetus can be detected in the maternal serum in concentrations about 100-fold less than in the amniotic fluid. The serum concentrations continue to rise until the third trimester and then fall to normal non-pregnant concentrations at delivery. The working group laid great emphasis on the need for counselling patients at all stages of the screening process. An "opting in" system was recommended so that the pregnant woman, having had a full opportunity to discuss the screening process, would then be able to make an informed decision on whether to have her blood assayed, with the implication of abortion if the fetus were found to have a neural tube defect. The group considered in detail the requirements of laboratories concerned with both serum and amniotic alphafetoprotein assay, and emphasised the need for high standards checked by external nationally organised quality control schemes. It recommended national and local monitoring of the scheme as a whole to provide epidemiological data on the frequency of neural tube defect and information on the number and type of cases detected (and missed) and the degree to which the prevalence of handicap was being reduced, and to help identify as yet unrecognised side effects ofthe programme. For Improved diagnosis and fetal malformation-The upper limit of "normal" maternal serum alphafetoprotein concentration is quite arbitrary. The higher the point is set the more specific the test becomes. Fewer normal pregnancies are included and fewer amniocenteses, with their attendant risks, are carried out. The penalty paid is that the sensitivity of the test falls and more fetuses with neural tube defect go unrecognised. In contrast, lowering the intervention point increases the proportion of fetuses with neural tube defect detected but also increases the number of normal pregnancies put at risk by amniocentesis.
In 30% of pregnancies the woman is uncertain about her dates and gestation should be checked by ultrasound.2 This frequently shows that gestation has been underestimated and that the apparently raised concentration of alphafetoprotein in the serum is in fact appropriate for the corrected gestational age. In those pregnancies in which gestational age has been overestimated, however, false-negative results may not be recognised, and this may account for some of the cases-about 20% ofall cases ofopen spina bifida-that are currently missed by maternal serum alphafetoprotein screening.14 Clearly one important way by which results could be improved would be the use of ultrasound to determine gestational age in all pregnancies.
Difficulties in interpreting amniotic alphafetoprotein results-
Most results of amniotic alphafetoprotein assay are clearly within the normal or abnormal ranges for a particular gestational age, but some are in a "grey area" of uncertainty. In some centres obstetricians investigate such pregnancies by detailed high-resolution ultrasound scanning to identify a neural tube defect or other defect before carrying out termination. The ability of a skilled obstetrician to use specialised ultrasound to detect fetal malformation is remarkable and is still improving.20 Though a negative result on the ultrasound scan does not guarantee a normal fetus the technique is the best single way of confirming diagnosis. New biochemical tests now undergoing evaluation include determining amniotic acetylcholinesterase2l 22 Screening andperinatal morbidity-The use ofmaternal serum alphafetoprotein concentrations as an indicator of fetal wellbeing was suggested28 before anyone knew of the association between alphafetoprotein and neural tube defect. Now several studies have shown that persistently raised concentrations at 16-20 weeks of gestation is associated with an increased fetal risk, even in the absence of neural tube defect. Wald and his colleagues29 30 have reported an increased risk of miscarriage, low birth weight, and perinatal death in such pregnancies. Further, in Brock's3' experience concentrations exceeding four times the median were associated with spontaneous abortion, stillbirth, or neonatal death in twothirds of pregnancies in which twins and neural tube defect had been excluded. We have shown32 that the increased fetal risk associated with raised maternal serum alphafetoprotein is not due to amniocentesis. In the pregnancies that we studied high concentrations were associated with significant increases in the frequency of undesired fetal loss and low birth weight, and an increased sex ratio (table I) . Indeed, since a persistently Hobel' s approach to preventing prematurity and the improved management of intrauterine fetal growth retardation is the identification of high-risk pregnancies-by analysing epidemiological and other factors before and during pregnancy. Reliable identification of high-risk fetuses can lead to carefully designed, randomised intervention studies such as the one now going on in Oxford (Wald, personal communication) . Here women with persistently raised alphafetoprotein concentrations in their serum are being randomly allocated either to routine antenatal care or to treatment with beta-mimetic drugs to prevent premature labour. Knowing which women to transfer for delivery to a maternity hospital that can provide mechanical ventilation would also be valuable, since facilities for assisted respiration greatly improve the prospects for survival without handicap in infants of very low birth weight. 4' 42 The time is surely ripe to include maternal serum alphafetoprotein assays in prospective collaborative studies designed to prevent handicap. Meanwhile a high concentration of alphafetoprotein detected in the serum must strongly influence the further counselling of women taking part in screening programmes even if ultrasound scans and the alphafetoprotein concentration in the amniotic fluid are normal. 3' Prospects for true prevention of neural tube defect-The causation of neural tube defect remains obscure despite many epidemiological and other studies. 43 44 The large differences in frequency around the world suggest important environmental influences, and the mother's diet may be particularly important. In a recent prospective intervention study45 women who had previously had a fetus with a neural tube defect were given vitamin supplements for at least a month before and for two months after conception, to cover the period of neural tube closure. There was a highly significant reduction among women receiving the supplements in the expected frequency of fetuses with a neural tube defect (table II) . This was not, however, a truly randomised control trial and the results must await independent confirmation.
Conclusions-Any community considering introducing maternal serum alphafetoprotein screening should take into account the following: (a) the local incidence of neural tube defect; (b) the irreducible minimum risk of amniocentesis; (c) laboratory variables of screening, including the sensitivity and specificity of the tests used; (d) the current availability of and future prospects for counselling and the obstetric, ultrasound, and laboratory resources; (e) a local consensus on the ethical problems.
Even if the recent trend towards a falling incidence of neural tube defect46 is accelerated by giving mothers dietary supplements, neural tube defect will not disappear. The logistic problems of universal dietary supplements before conception would be considerable, and if the medical campaign against smoking is anything to go by instant success is unlikely. In any case, ifmaternal serum alphafetoprotein proves to be a valuable predictor of other risks to the fetus this will be additional justification for introducing maternal serum alphafetoprotein screening programmes nationally.
